Sort by
Refine Your Search
-
Listed
-
Employer
- University of Oxford
- ;
- DURHAM UNIVERSITY
- Durham University
- KINGS COLLEGE LONDON
- University of London
- AALTO UNIVERSITY
- King's College London
- UNIVERSITY OF VIENNA
- Nature Careers
- University of Nottingham
- Aston University
- MOHAMMED VI POLYTECHNIC UNIVERSITY
- University of Cambridge
- ; University of Copenhagen
- Cardiff University
- Heriot Watt University
- Imperial College London
- Royal College of Art
- University of Birmingham
- University of Cambridge;
- University of Hull
- University of Liverpool
- 13 more »
- « less
-
Field
-
combines ground-breaking basic research with the expertise of clinicians and clinician scientists from the Centre for Experimental Cancer Medicine and the Barts NHS Trust to achieve improvements in cancer
-
’ (PHOENIX), led by Associate Professor Thomas Aubry (University of Oxford). Using a combination of laboratory experiments, field work and numerical modelling, PHOENIX aims to improve our understanding
-
the polymers will be investigated to discover earth-abundant and synergic metal combinations and to elucidate the minimum energy inputs to enable effective polymer production. The research will involve catalyst
-
' CPL detection technology. CSI's combine organic short-lived (ns) green/blue emitters and chiral (CPL active) red/green (terbium/europium) long-lived (ms) emitters embedded into transparent polymer
-
orchestration, with applications to Finance. This post is advertised as full-time (35 hours per week). We are open to considering requests for hybrid working (on a non-contractual basis) that combine a mix of
-
compartments. The successful candidate will combine cutting-edge in vitro and in vivo infection models, and both microscopy and flow cytometry-based readouts of infection to develop their independent research
-
The successful candidate will combine cutting-edge microbiological, biochemical, molecular genetics, and comparative genomics-based approaches to develop their independent research project and will also
-
of an automated workflow to determine the drug susceptibility and resistance liabilities of novel antifungal drugs, across a wide range of fungal pathogens, both alone and in combination with existing antifungal
-
organ-chip models. These include different combinations of tissues such as synovium, cartilage, bone, meniscus, blood vessels and fat, as well as conditions such as inflammation, osteoarthritis and
-
to determine the drug susceptibility and resistance liabilities of novel antifungal drugs, across a wide range of fungal pathogens, both alone and in combination with existing antifungal drugs. Areas of interest